1. |
Bohuon C. A brief history of procalcitonin[J]. Intensive Care Med, 2000, 26(Suppl 2):S146-S147.
|
2. |
Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection[J]. Lancet, 1993, 341(8844):515-518.
|
3. |
Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects[J]. J Clin Endocrinol Metab, 1994, 79(6):1605-1608.
|
4. |
Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults[J]. Clin Infect Dis, 2007, 44(Suppl 2):S27-S72.
|
5. |
Connert S, Stremmel W, Elsing C. Procalcitonin is a valid marker of infection in decompensated cirrhosis[J]. Z Gastroenterol, 2003, 41(2):165-170.
|
6. |
Ho KM. Combining sequential organ failure assessment (SOFA) score with acute physiology and chronic health evaluation (APACHE)Ⅱ score to predict hospital mortality of critically ill patients[J]. Anaesth Intensive Care, 2007, 35(4):515-521.
|
7. |
Vincent JL, Moreno R, Takala J, et al. The SOFA score to describe organ dysfunction/failure[J]. Intensive Care Med, 1996, 22(7):707-710.
|
8. |
Ethan AH, Alvin S. Management of community-acquired pneumonia[J]. J Assoc Physicians India, 2013, 61(7 Suppl):20-23.
|
9. |
Vincent JL. Procalcitonin:THE marker of sepsis?[J]. Crit Care Med, 2000, 28(4):1226-1228.
|
10. |
Casado FJ, Procalcitnin BQ. A new maker for bacterial infection[J]. An Esp Pediatr, 2001, 54(8):69.
|
11. |
Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects[J]. J Clin Endocrinol Metab, 1994, 79(6):1605-1608.
|
12. |
Christ-Crain M, Schuetz P, Huber AR, et al. Procalcitonin-importance for the diagnosis of bacterial infections[J]. Ther Umsch, 2008, 65(9):559-568.
|
13. |
Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new marks of inflammation in patients with sepsis[J]. J Clin Chem Lab Med, 1999, 37(3):363-368.
|
14. |
杜斌, 陈德昌, 潘家绮, 等. 降钙素原与白介素-6的相关性优于传统的炎症指标[J]. 中国危重病急救医学, 2002, 14(8):474-477.
|
15. |
Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia[J]. Wien Klin Wochenschr, 2006, 118(5/6):170-174.
|
16. |
Jereb M, Lunaček NK, Kotar T, et al. Procalcitonin in hantavirus infections[J]. Scand J Clin Lab Invest, 2011, 71(4):287-291.
|
17. |
Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care[J]. Arch Intern Med, 2008, 168(18):2000-2007.
|
18. |
Charles PE, Dalle F, Aho S, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients[J]. Intensive Care Med, 2006, 32(10):1577-1583.
|
19. |
Masiá M, Gutiérrez F, Shum C, et al. Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index[J]. Chest, 2005, 128(4):2223-2229.
|
20. |
Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia[J]. Intensive Care Med, 2006, 32(3):469-472.
|
21. |
Reny JL, Vuagnat A, Ract C, et al. Diagnosis and follow-up of infections in intensive care patients:value of C-reactive protein compared with other clinical and biological variables[J]. Crit Care Med, 2002, 30(3):529-535.
|